SIV

Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen Planus

Retrieved on: 
Freitag, Mai 31, 2024
Toxicity, FDA, Male, OLP, Safety, LIPO, Tacrolimus, SIV, Institutional review board, Pain, Lichen planus, IRB, Female, Pharmaceutical industry

PITTSBURGH, May 31, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced the successful completion of its first Site Initiation Visit (SIV) for the Phase 2a trial evaluating LP-310 in the treatment of Oral Lichen Planus (OLP). With clearance received from the central Institutional Review Board (IRB), the Phase 2a trial is set to commence with site qualifications completed and patient recruitment underway.

Key Points: 
  • Patient recruitment is underway for Phase 2a multicenter, dose-ranging study
    PITTSBURGH, May 31, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced the successful completion of its first Site Initiation Visit (SIV) for the Phase 2a trial evaluating LP-310 in the treatment of Oral Lichen Planus (OLP).
  • With clearance received from the central Institutional Review Board (IRB), the Phase 2a trial is set to commence with site qualifications completed and patient recruitment underway.
  • Lipella’s Phase 2a trial is a multicenter, dose-ranging study involving adult male and female subjects experiencing symptomatic OLP.
  • Dr. Jonathan Kaufman, CEO of Lipella, expressed his enthusiasm, stating, “We are extremely pleased to announce the completion of the Site Initiation Visit for our Phase 2a trial of LP-310.

HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Freitag, März 22, 2024
SIV, Clinical trial, Hepatitis, Head, CPI, Serum, Hepatitis B, Partnership, HIV, Oncology, Gilead Sciences, Patient, Lung, Journal, Viral load, Pembrolizumab, HBV, Trial of the century, IND, Infection, Hepatocyte, Arenavirus, Antibody, Vaccination, Intellectual property, FDA, Liver, Animal, Pharmaceutical industry

“It was a defining year for HOOKIPA as we witnessed the powerful potential of our novel arenaviral immunotherapies in action.

Key Points: 
  • “It was a defining year for HOOKIPA as we witnessed the powerful potential of our novel arenaviral immunotherapies in action.
  • Data was initially presented in May 2023 and additional patient data was provided in October at the European Society for Medical Oncology Congress 2023.
  • HOOKIPA expects to initiate a Phase 1 clinical study of HB-500 in people with HIV in the second quarter of 2024.
  • In June 2023, the Company completed a $50.0 million public offering of common stock and non-voting convertible preferred stock.

ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update

Retrieved on: 
Donnerstag, März 14, 2024
SIV, Data, Combination, EGFR, Property, SPI, Patient, Sale, Attention deficit hyperactivity disorder, Syndrome, Lung cancer, IND, Myelodysplastic syndrome, Bank statement, Investment, Note, European, TNBC, ADHD, GAP, BioLite, DSM-IV codes, GMP, Investigational New Drug, MDS, Common stock, UCSF, NSCLC, Dietary supplement, Research, Good manufacturing practice, Cancer, University, Security (finance), Pancreatic cancer, Drug development, TGA, FDA, Map, Consultant, Variable, Toxicity, Metastasis, Patent, MDD, Triple-negative breast cancer, License, Long-term care, Net, US FDA, Pharmaceutical industry

As per the respective agreements, each of ABVC and BioLite received 23 million shares of AIBL stock (with an expected value of $10 per share).

Key Points: 
  • As per the respective agreements, each of ABVC and BioLite received 23 million shares of AIBL stock (with an expected value of $10 per share).
  • The Company entered a cooperation agreement on August 14, 2023, with Zhong Hui Lian He Ji Tuan, Ltd. (“Zhonghui”).
  • On February 06, 2024, ABVC acquired an additional real estate asset via an equity transfer of 703,495 shares at $3.50 per share to develop plant factories for ABVC’s botanical pipeline.
  • ABVC hopes the property will ultimately be used as an integrated platform for the global development of the Asian healthcare business and the medical, pharmaceutical, and biotechnology industries.

Autonomix Signs Key Clinical Agreements in Preparation to Begin March 2024 Human Clinical Trial

Retrieved on: 
Donnerstag, Februar 29, 2024
Nervous system, MEDLINE, POC, AMIX, Collateral damage, Pain, ChromeOS, Patient, Clinical trial, SIV, Disease, Naval ship, Ethanol, Medical imaging

THE WOODLANDS, TX, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced it has entered into a clinical site agreement with “АКFА MEDLINE" Ltd., for its PoC human clinical trial evaluating the use of transvascular RF ablation for the treatment of pancreatic cancer pain.

Key Points: 
  • Additionally, Autonomix announced the selection of Clinical Accelerator and Qmed, full service Clinical Research Organizations (CROs) specializing in medical devices to support the PoC human clinical trial.
  • Clinical Accelerator will be responsible for managing the clinical operations in country, including recruiting patients, SIV work, and patient treatment records and Qmed will be responsible for managing protocol and trial reporting, as well as managing patient data.
  • Lori Bisson, Chief Executive Officer of Autonomix commented, “We are pleased to execute these important agreements and final steps towards commencing patient enrollment in our first PoC human clinical trial.
  • Twenty (20) subjects will be enrolled at one clinical trial site for the trial.

Oakland Zoo Provides Care for Recently Seized Marmoset Monkey

Retrieved on: 
Donnerstag, Februar 8, 2024
Malnutrition, Human, ARCAS, Medicine, Social media, Forehead, Housing, Ulna, Zoonosis, Port, Oakland Zoo, Primate, California Department, Keepers, Health, Seizure, CDFW, WCN, Movement, Trauma, SIV, Animal, Behavior, TB, Hospital, Anesthesia, Risk, Research, Pet, Zoo, Rabies, Quarantine, Rehabilitation, SFO, HIV, Music, Female

OAKLAND, Calif., Feb. 8, 2024 /PRNewswire-PRWeb/ -- On January 20th, Oakland Zoo worked with the California Department of Fish and Wildlife (CDFW) and the Wildlife Confiscation Network (WCN) to rescue an illegally owned female marmoset in a seizure of the monkey from a private residence in southern California. The owner was arrested on other charges unrelated to having the female marmoset and was made aware in advance that the animal was to be seized by authorities. Oakland Zoo was contacted after San Diego Zoo and Los Angeles Zoo (other Association of Zoos and Aquariums accredited partners) could not take in the marmoset due to the capacity concerns related to other WCN rescues they were involved with.

Key Points: 
  • Oakland Zoo is caring for a female marmoset named Estrela, an illegally owned pet, after being seized by California Department of Fish and Wildlife officials.
  • Oakland Zoo was contacted after San Diego Zoo and Los Angeles Zoo (other Association of Zoos and Aquariums accredited partners) could not take in the marmoset due to the capacity concerns related to other WCN rescues they were involved with.
  • Estrela will remain in the care of the Oakland Zoo and housed in their Veterinary Hospital until she has completed her quarantine period.
  • For years, animals confiscated by officials at SFO, and the Port of Oakland have been brought to Oakland Zoo for treatment, care, and permanent sanctuary.

HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus

Retrieved on: 
Montag, November 20, 2023
SIV, Food, Antigen, IND, Antibody, Arenavirus, FDA, The Mark of Gideon, Simian immunodeficiency virus, Vaccination, NPJ, Animal, HIV, Vaccine, LCMV, Gilead Sciences, Viral load

HOOKIPA is responsible for advancing the HIV program through the completion of a Phase 1b clinical trial.

Key Points: 
  • HOOKIPA is responsible for advancing the HIV program through the completion of a Phase 1b clinical trial.
  • The analyses published were conducted with a simian immunodeficiency virus (SIV) model, commonly used in a preclinical setting as a surrogate to HIV.
  • One vector is based on lymphocytic choriomeningitis virus (LCMV) as its arenaviral backbone; another vector is based on Pichinde virus (PICV).
  • HB-500 is one of two separate development programs in HOOKIPA’s collaboration and license agreement with Gilead.

ABVC BioPharma Reports Third Quarter 2023 Financial and Operational Results

Retrieved on: 
Mittwoch, November 15, 2023
CNS, Sale, CSMC, Retina, Patient, Triple-negative breast cancer, Attention deficit hyperactivity disorder, Cayman, Investigational New Drug, US FDA, Licensed production, Cancer, Power purchase agreement, SIV, Security (finance), Toxicity, Plasma protein binding, Syndrome, IND, Surgeon, TGA, BioLite, ADHD, Taiwan Stock Exchange, Sales management, Hydrogel, MDD, Pancreatic cancer, Depression, GMP, Good manufacturing practice, Bank statement, UCSF, MDS, University, Partnership, Phase, Drug development, Research, ANDA, Warrant, FDA, Dietary supplement, West Pharmaceutical Services, Share (finance), Pharmaceutical industry, Cryptocurrency, Qiu Zhonghui

FREMONT, CA, Nov. 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"): Today, a biotechnology company specializing in botanically based solutions that deliver high efficacy and low toxicity to improve health outcomes announced its financial and operating results for the third quarter of 2023.

Key Points: 
  • FREMONT, CA, Nov. 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"): Today, a biotechnology company specializing in botanically based solutions that deliver high efficacy and low toxicity to improve health outcomes announced its financial and operating results for the third quarter of 2023.
  • During July 2023, the warrant exercise price was reset to $3.5 under the issuance of common stock about securities purchase agreement on July 2023.
  • During the third quarter of 2023, the Company issued to Zhonghui an aggregate of 370,000 shares of the Company's common stock at a per-share price of $20.
  • "We are delighted with our remarkable accomplishments and meaningful progress in 2023, and look forward to upcoming reports to end 2023 on a positive note," said Uttam Patil, Ph.D., Chief Executive Officer of ABVC BioPharma.

Can HIV be cured using gene editing? We will soon find out

Retrieved on: 
Mittwoch, November 8, 2023
Rat, Artery, Technology, Heart, Human, HIV, US Foods, Sickle cell disease, SIV, Virus, Cell, Research, Mouse, Temple University, Disease, Effectiveness, Bacteria, Animal, Eye, Infection, Safety, Excision, Patient, DSM-IV codes, DNA, Vaccine, Pharmaceutical industry, Adhesive, CRISPR

To catch this virus was initially a death sentence, but today, thanks to antiretroviral drugs, it can be kept in check.

Key Points: 
  • To catch this virus was initially a death sentence, but today, thanks to antiretroviral drugs, it can be kept in check.
  • A small biotech company in San Francisco called Excision BioTherapeutics is trying to change that with its infusion, called EBT-101.
  • Despite the availability of antiretroviral drugs, hundreds of thousands of people still die from Aids each year.
  • Testing on larger groups of people and making the therapy affordable for everyone with HIV are crucial because the disease is more prevalent in poorer countries.

Indium Tin Oxide Market size to increase by USD 213.87 million between 2022 to 2027| Amalgamated Metal Corp. PLC, American Elements, Diamond Coatings Inc. and more among key companies- Technavio

Retrieved on: 
Mittwoch, September 27, 2023
Diamond, Nanoparticle, ENAM, Smelting, Transparency, SIV, London, Silver, Electrochromism, Merck Group, Indium, Temperature, USD, FRP, Indium phosphide, NE, Aluminium, Semiconductor, American Elements, Chemical substance, Application, Others, Geography, Photovoltaics

Increasing dependency on renewable energy sources is notably driving the indium tin oxide market.

Key Points: 
  • Increasing dependency on renewable energy sources is notably driving the indium tin oxide market.
  • Buy the report now for detailed company information
    Indium Tin Oxide Market 2023-2027: Company Analysis:
    Ulvac Inc.: The company offers indium tin oxide products such as NE 5700 and SIV series systems.
  • View Free PDF Sample Report
    Indium Tin Oxide Market 2023-2027: Market Dynamics:
    Driver - The increasing usage of touchscreen devices is a key factor driving market growth.
  • For more information on drivers, trends and challenges, download the free sample report here
    Indium Tin Oxide Market 2023-2027: Key Highlights
    How do the major trends impact the market?

Excision BioTherapeutics Announces Gene Therapy Publication of Pre-Clinical Data Supporting its First-in-Class CRISPR-Based Gene Therapy Candidate Designed to Functionally Cure HIV-1

Retrieved on: 
Donnerstag, August 17, 2023
Tissue, HIV/AIDS, DNA, CRISPR, Herpes simplex virus, Therapy, Gene, Senior, HIV, Temple University, SIV, Gene editing, Clinical trial, ART, Toxicity, Infection, Doctor of Philosophy, Science, Northwest Biotherapeutics, Animal, Risk, Primate, SAN, Blood, Safety, Autopsy, Pharmaceutical industry, Vaccine, Excision, Research, Medicine

The data support the safety, biodistribution, and on-target editing of Excision’s EBT-101 program targeting HIV, which is being evaluated in first-in-human Phase 1/2 clinical trials.

Key Points: 
  • The data support the safety, biodistribution, and on-target editing of Excision’s EBT-101 program targeting HIV, which is being evaluated in first-in-human Phase 1/2 clinical trials.
  • “We are very excited by the positive data generated in this study, which set the foundation for an important first-in-human clinical trial of our lead candidate, EBT-101,” said Daniel Dornbusch, Chief Executive Officer of Excision.
  • The newly published data supplement the efficacy data generated in previous pre-clinical studies of EBT-101, demonstrating excision of integrated proviral SIV DNA in vivo, without any detectable off-target effects.
  • “These newly published results demonstrate the tremendous potential of EBT-101 to shape the future of HIV therapeutics,” said Dr. Khalili.